Agios Pharma (AGIO) Reports Results from Phase 3 ACTIVATE-KidsT Study of Mitapivat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Agios Pharma (AGIO) PT Raised to $55 at RBC Capital
August 2, 2024 6:21 AM EDTRBC Capital analyst Kennen MacKay raised the price target on Agios Pharma (NASDAQ: AGIO) to $55.00 (from $53.00) while maintaining a Outperform rating.
The analyst comments "AGIO reported its 2Q24 update concurrent with the ACTIVATE-KidsT (pediatric PKD) topline results which missed the prespecified... More
